SG11201808913WA - Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer - Google Patents

Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer

Info

Publication number
SG11201808913WA
SG11201808913WA SG11201808913WA SG11201808913WA SG11201808913WA SG 11201808913W A SG11201808913W A SG 11201808913WA SG 11201808913W A SG11201808913W A SG 11201808913WA SG 11201808913W A SG11201808913W A SG 11201808913WA SG 11201808913W A SG11201808913W A SG 11201808913WA
Authority
SG
Singapore
Prior art keywords
international
agonist
toll
receptor
treating cancer
Prior art date
Application number
SG11201808913WA
Inventor
Cristiana Guiducci
Edwina Naik
Robert Milley
Stewart Chipman
Original Assignee
Dynavax Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynavax Tech Corp filed Critical Dynavax Tech Corp
Publication of SG11201808913WA publication Critical patent/SG11201808913WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464488—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/39—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by a specific adjuvant, e.g. cytokines or CpG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds

Abstract

II o Unvaccinated D-04-Alum-OVApep SC D61-04-Alum-OVApep IT D61-04-Alum IT ,S - 2000- E1500- - a - .) 1000- E 500- t; 400 300 200 100 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/181128 Al 19 October 2017 (19.10.2017) WIPO I PCT (51) International Patent Classification: A61K 39/00 (2006.01) A61K 47/36 (2006.01) A61K 39/39 (2006.01) A61K 31/711 (2006.01) A61K 47/02 (2006.01) A61P 35/00 (2006.01) A61K 47/10 (2017.01) (21) International Application Number: PCT/US2017/027788 (22) International Filing Date: 14 April 2017 (14.04.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/323,622 15 April 2016 (15.04.2016) US 62/439,438 27 December 2016 (27.12.2016) US (71) Applicant: DYNAVAX TECHNOLOGIES CORPORA- TION [US/US]; 2929 Seventh Street, Suite 100, Berkeley, CA 94710 (US). (72) Inventors: GUIDUCCI, Cristiana; 1048 Talbot Avenue, Albany, CA 94706 (US). NAIK, Edwina; 5308 Genoa Street, Oakland, CA 94608 (US). MILLEY, Robert, J.; 3061 Bridsall Avenue, Oakland, CA 94619 (US). CHIP- MAN, Stewart, D.; 11042 Forest Ln NE, Bainbridge Is- land, WA 98110 (US). (74) Agents: LEKUTIS, Christine et al.; Morrison & Foerster LLP, 425 Market Street, San Francisco, CA 94105-2482 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) = (54) Title: INTRATUMORAL ADMINISTRATION OF PARTICLES CONTAINING A TOLL-LIKE RECEPTOR 9 AGONIST AND A TUMOR ANTIGEN FOR TREATING CANCER FIG. 11A ns *** (57) : The present disclosure relates to methods for treating cancer by intratumoral delivery of particles containing a Toll- like receptor 9 agonist (TLR9) and a tumor antigen, in which the TLR9 agonist is a polynucleotide or a chimeric compound thereof. The methods of the present disclosure involve injection of the particles into at least one tumor, and are effective for treating both in - jected and uninjected tumors of a mammalian subject. Additionally, the present disclosure provides immunogenic compositions con- taining the particles, as well as methods of manufacture thereof. 1111111111111101110111111111110101111101110111H0111011101111101111111111111111111 W O 20 17 / 18 1128 Al
SG11201808913WA 2016-04-15 2017-04-14 Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer SG11201808913WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662323622P 2016-04-15 2016-04-15
US201662439438P 2016-12-27 2016-12-27
PCT/US2017/027788 WO2017181128A1 (en) 2016-04-15 2017-04-14 Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer

Publications (1)

Publication Number Publication Date
SG11201808913WA true SG11201808913WA (en) 2018-11-29

Family

ID=60042047

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201808913WA SG11201808913WA (en) 2016-04-15 2017-04-14 Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer

Country Status (10)

Country Link
US (1) US20170326232A1 (en)
EP (1) EP3442568A4 (en)
JP (1) JP2019515900A (en)
KR (1) KR20180129903A (en)
CN (1) CN109475612A (en)
AU (1) AU2017250348A1 (en)
CA (1) CA3020873A1 (en)
MX (1) MX2018012391A (en)
SG (1) SG11201808913WA (en)
WO (1) WO2017181128A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180021700A (en) * 2015-05-29 2018-03-05 다이나박스 테크놀로지 코퍼레이션 Intrapulmonary administration of polynucleotide Toll-like receptor 9 agonists to treat lung cancer
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)
EP3727447A1 (en) 2017-12-19 2020-10-28 Massachusetts Institute of Technology Antigen-adjuvant coupling reagents and methods of use
WO2019200238A1 (en) 2018-04-14 2019-10-17 Dynavax Technologies Corporation Combinations including a cpg-c type oligonucleotide and a histone deacetylase inhibitor for treating cancer
TW202012395A (en) 2018-04-14 2020-04-01 德商４Ｓｃ製藥公司 Pharmaceutical combination products comprising a histone deacetylase (hdac) inhibitor and a tlr7 agonist and/or tlr8 agonist for the treatment of cancer
WO2020081398A1 (en) 2018-10-14 2020-04-23 Dynavax Technologies Corporation Combination including a cpg-c type oligonucleotide and a pd-1 antagonist for treating breast cancer
SG11202100854TA (en) 2018-10-16 2021-05-28 US Nano Food & Drug INC Intratumor injection formulation
JP2022538974A (en) 2019-06-26 2022-09-07 マサチューセッツ インスチテュート オブ テクノロジー Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
MX2022005633A (en) * 2020-01-10 2022-06-14 Sbi Biotech Co Ltd Novel tlr9 agonists.
CN114929213A (en) 2020-04-13 2022-08-19 美国纳米食品药品公司 Alkaline chemotherapeutic intratumoral injection composition
CA3196274A1 (en) * 2020-09-22 2022-03-31 Trisalus Life Sciences, Inc. Cancer therapy using toll-like receptor agonists
KR20230121995A (en) * 2020-09-22 2023-08-22 트라이살루스 라이프 사이언시즈, 인크. Cancer Therapy Using Toll-Like Receptor Agonists
CN114099535B (en) * 2020-12-10 2023-01-03 南京吉迈生物技术有限公司 Toll-like receptor 9 (TLR 9) agonist hydrogel immunomodulatory compositions
CA3232439A1 (en) 2021-09-16 2023-03-23 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
KR20230153790A (en) 2022-04-29 2023-11-07 주식회사 레고켐 바이오사이언스 Imidazo[4,5-c]pyridine derivative compounds as TLR7/8 modulators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723832B1 (en) * 1996-10-03 2004-04-20 Ludwig Institute For Cancer Research Isolated peptides corresponding to amino acid sequences of NY-ESO-1, which bind to MHC Class I and MHC Class II molecules, and uses thereof
CN100546998C (en) * 2002-12-23 2009-10-07 戴纳伐克斯技术股份有限公司 Immunostimulatory sequence oligonucleotides and using method
US8158768B2 (en) * 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US20080124366A1 (en) * 2006-08-06 2008-05-29 Ohlfest John R Methods and Compositions for Treating Tumors
BRPI0814899A2 (en) * 2007-08-21 2015-02-03 Dynavax Tech Corp COMPOSITION, VACCINE, METHOD FOR SOFTENING ONE OR MORE SYMPTOMS ASSOCIATED WITH INFLUENZA VIRUS INFECTION IN AN INDIVIDUAL AND METHOD TO REDUCE THE PROBABILITY OF INFLUENCE VIRUS INFECTION IN AN INDIVIDUAL "
WO2010002940A2 (en) * 2008-06-30 2010-01-07 Dynavax Technologies Corporation Heterogeneous synthesis of multivalent chimeric immunomodulatory compounds using platform based molecules
CA2847332A1 (en) * 2011-08-31 2013-03-07 Mie University Vaccine preparation for cancer treatment
BR112015000483B1 (en) * 2012-07-13 2022-05-17 S-Target Therapeutics Gmbh IMMUNO REGULATORY OR SENSITIZING VACCINE, KIT TO PREPARE THE VACCINE AND METHOD USED TO PREPARE THE VACCINE TO TRIGGER AN IMMUNE RESPONSE FROM IGG
WO2016118932A1 (en) * 2015-01-23 2016-07-28 Dynavax Technologies Corporation Branched and linear chimeric compounds, polynucleotides, uses and methods for preparation thereof
US20180117171A1 (en) * 2015-04-01 2018-05-03 President And Fellows Of Harvard College Immunoconjugates for programming or reprogramming of cells
WO2016184862A1 (en) * 2015-05-18 2016-11-24 Oncoqr Ml Gmbh Her2/neu immunogenic composition

Also Published As

Publication number Publication date
MX2018012391A (en) 2019-02-14
CA3020873A1 (en) 2017-10-19
EP3442568A1 (en) 2019-02-20
JP2019515900A (en) 2019-06-13
EP3442568A4 (en) 2019-12-18
US20170326232A1 (en) 2017-11-16
KR20180129903A (en) 2018-12-05
CN109475612A (en) 2019-03-15
WO2017181128A1 (en) 2017-10-19
AU2017250348A1 (en) 2018-10-11

Similar Documents

Publication Publication Date Title
SG11201808913WA (en) Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer
SG11201806515RA (en) Eribulin-based antibody-drug conjugates and methods of use
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201901126UA (en) Combination therapy for cancer
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201808799SA (en) Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
SG11201903331QA (en) Restimulation of cryopreserved tumor infiltrating lymphocytes
SG11201807660QA (en) Cyclic di-nucleotide compounds and methods of use
SG11201811432WA (en) Rna for cancer therapy
SG11201908092RA (en) Anti-tigit antigen-binding proteins and methods of use thereof
SG11201811290VA (en) Compositions and methods for the depletion of cd117+cells
SG11201811292RA (en) Compositions and methods for the depletion of cells
SG11201808125RA (en) Methods for solid tumor treatment
SG11201805645QA (en) Lsd1 inhibitors
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201908919XA (en) Combination therapies targeting pd-1, tim-3, and lag-3
SG11201408769QA (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
SG11201900501RA (en) Cannabis composition
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201901020RA (en) Anti-siglec-7 antibodies for the treatment of cancer
SG11201909837YA (en) Methods for treating lung disorders
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201809751XA (en) Egfr inhibitor compounds
SG11201906853QA (en) Anti-rsv monoclonal antibody formulation